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Abstract
This review addresses surfactant alterations and treatment in lung transplant ischemiareperfusion injury. Lung ischemia
reperfusion injury damages the endogenous surfactant system as a result of the production of reactive oxygen species,
proteolytic enzymes and (phospho)lipases. Surfactant is composed of phospholipids and proteins and its main function is to
reduce the surface tension inside the alveolus. Impairment of surfactant will cause atelectasis, influx of serum proteins,
pulmonary edema, decreased lung compliance and impaired gas exchange. Surfactant therapy restores the quantity and
composition of surfactant and reduces the inhibitory effect of serum proteins; other effects are that it serves as an antioxidant
and anti-inflammatory agent. Pretreatment may be more beneficial than treatment after the development of lung ischemia
reperfusion injury. However, the cost of surfactant must be weighed against the clinical outcome.
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Lung transplantation
Lung transplantation is nowadays a well-accepted
treatment option for patients with end-stage pul-
monary diseases. Although improvements in lung
preservation, pre- and postoperative care and surgi-
cal techniques have been made, the outcome of
human lung transplantation remains limited (1,2).
Development of primary acute graft failure (PAGF)
is the main cause of early morbidity and mortality
after lung transplantation, resulting in a 1-year
survival rate of :/80% (1,2). Moreover, long-term
prognosis is also limited (5-year survival B/50%) due
to the development of bronchiolitis obliterans syn-
drome (BOS) (1). Lung ischemiareperfusion injury
(LIRI) is thought to contribute significantly to both
PAGF and BOS (1,3,4).
PAGF
PAGF, which symptomatically resembles the acute
respiratory distress syndrome (ARDS), usually
develops within 72 h after transplantation (5).
Symptoms of PAGF consist of non-cardiogenic
pulmonary edema, increased pulmonary artery
pressure, decreased lung compliance and impaired
gas exchange (59). Histological analysis of PAGF
lungs shows diffuse alveolar damage with micro-
atelectasis. Although :/97% of the recipients show
some degree of reperfusion edema on chest X-ray,
severe LIRI occurs in 1530% of lung transplant
recipients (6).
Experimental studies of LIRI (710) have shown
that abnormalities and depletion of pulmonary
surfactant (surfactant) contribute significantly to
the symptoms seen in PAGF of the lung. Further-
more, surfactant obtained by means of bronchoal-
veolar lavage of human lung transplant recipients
demonstrated surfactant dysfunction up to 7 years
after transplantation, thereby contributing to lung
malfunction (11).
Pulmonary surfactant is essential for normal
breathing, as it diminishes the surface tension
at the airfluid interface inside the alveolus
(12). Herewith, the alveolus is kept open at the
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end of expiration and fluid homeostasis is pre-
served (12).
BOS
Although severe LIRI contributes considerably to
the development of PAGF, the impact of LIRI on
long-term mortality is still the subject of debate.
The major obstacle to long-term survival is the
development of post-lung transplant BOS, which is
associated with chronic transplant dysfunction
(1,13). BOS affects :/50% of patients who survive
for /3 months after transplantation (13). The
pathogenesis of BOS is not completely understood,
but appears to involve a ‘‘response to injury’’ type of
pattern, where multiple injuries may finally result in
BOS (Fig. 1). Both donor characteristics and trans-
plant procedure complications may result in early
lung injury. Reperfusion injury may worsen early
lung injury, whereafter rejection and alloantigen-
independent factors (pneumonia, cytomegalovirus)
can act as subsequent injuries and increase the risk of
BOS (2,3,13,14).
LIRI
LIRI predominantly occurs with lung transplanta-
tion. However, LIRI symptoms have also been
described after cardio-pulmonary bypass, isolated
lung perfusion and pulmonary sleeve resection.
As severe LIRI plays a significant role in the
development of PAGF after lung transplantation
and as LIRI is an early participant in the multiple-
hit theory of BOS, treatment of LIRI may decrease
early morbidity and mortality after LIRI, but may
also prevent or delay the onset of BOS, thereby
influencing the late morbidity and mortality of lung
transplantation.
Pathophysiology
Ischemia can be defined as a blood (oxygen)
deficiency in the lung caused by constriction or
obstruction of its blood vessels. Reperfusion occurs
when the blood flow to the organ is restored. During
the transplantation period, the lung is stored
hypothermically to reduce the rate of biochemical
reactions, which results in decreased degradation
of important cellular components. Nevertheless,
adenosine triphosphate (ATP) is depleted during
ischemia, which ultimately causes inactivation of
ATP-dependent membrane pumps, accumulation
of intracellular calcium, the formation of eicosanoids
and reactive oxygen species (ROS), inflammation
and cell death (Fig. 2) (2,15).
Inactive ATP-dependent membrane pumps and
intracellular calcium accumulation
Under normal conditions, the action of the
Na/K-ATP synthase (ATPase) pump sets up a
Fig. 1. Lung transplantation: a multiple-hit theory for the development of BOS.
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gradient of high extracellular Na relative to
intracellular levels, which in turn drives the
Na/Ca2-exchanger, so that Ca2 is pumped
out of the cell. During ATP depletion, the
Na/K-ATPase pump becomes inactivated, lead-
ing to an increase in intracellular Na. As a result,
the Na/Ca2 pump will not function, causing
Ca2 to accumulate inside the cell. Other mechan-
isms contributing to high intracellular Ca2 levels
are an inactive plasmalemmal ATP-dependent Ca2
pump, liberation of stored cytoplasmic Ca2 due to
acidosis and a decreased uptake by the sarcoplasmic/
endoplasmic reticulum (2,15).
Cytosol-elevated Ca2 activates phospholipase
A2, which results in the induction of arachidonic
acid. Arachidonic acid is normally incorporated in
the cell membrane and functions as a precursor for
the production of eicosanoids, consisting of throm-
boxanes, leukotrienes, prostacyclin and prostaglan-
dins. Whereas thromboxanes are predominantly
produced by platelets, leukotrienes are formed by
leukocytes, prostacyclin by endothelial cells and
prostaglandins by smooth muscle cells. The effects
of eicosanoids are various but include vasoconstric-
tion, activation of adhesion molecules, an increase in
capillary permeability and the accumulation and
extravasation of neutrophils (2,15).
Finally, increased intracellular Ca2 causes trans-
formation of xanthine dehydrogenase into xanthine
oxidase, thereby facilitating the production of ROS,
as described in the next section (2,15).
Production of ROS
In the aerobic setting, ATP is converted to
urea and xanthine by the effect of xanthine
dehydrogenase. However, due to the formation of
xanthine oxidase in LIRI, hypoxanthine is broken
down into ROS at the moment of reoxygenation.
A second system for generating ROS is the
reduced nicotinamide adenine dinucleotide phos-
phate oxidase system, which is predominantly
present on the membrane surfaces of monocytes,
macrophages, neutrophils and endothelial cells and
catalyzes the reduction of oxygen to superoxide
and hydrogen peroxide. The superoxide anion,
Fig. 2. Pathophysiology of LIRI. See text for details. AMP/adenosine monophosphate.
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hydrogen peroxide and hydroxyl radical, which are
all part of the ROS family, are very unstable and
damage cellular membranes by lipid peroxidation
(2,15).
Inflammation
LIRI causes release of proinflammatory cytokines by
macrophages. Consequently, neutrophils and lym-
phocytes are recruited into the lung. Because of the
expression of adhesion molecules on endothelium
and leukocytes, leukocytes roll, adhere to and
extravasate into the lung tissue. Macrophages and
neutrophils contribute to cellular damage by the
production of ROS and several other mediators,
such as proteolytic enzymes, lysozyme and lactofer-
rin (2,15).
Studying LIRI
Several experimental models can be used to study
treatment modalities for LIRI and its pathophysiol-
ogy. Although the best model is obviously a lung
transplantation model, this is a very time-consuming
procedure, especially in small animals, and is tech-
nically difficult, often with high mortality rates.
Therefore, an in situ lung clamp model, in which
the bronchus, pulmonary veins and artery of
(usually) the left lung are clamped to induce LIRI,
has been developed. The clamping time generally
ranges from 60 to 150 min (10,16,17). Although this
model is technically much easier than the aforemen-
tioned transplantation model, it still has some
disadvantages. Firstly, only warm ischemia can be
studied as the lung is kept in situ. Furthermore, no
preservation solutions are used and mortality may
still be high because the animals are (preferably)
ventilated after reperfusion for as short a period as
possible due to the confounding effects of ventilation
on LIRI (18).
Although the clamp model does not totally
resemble the events of real lung transplantation,
the symptoms of LIRI found in this model approx-
imate those seen with PAGF. The macroscopic result
of severe LIRI (120 min) is demonstrated in Fig. 3.
Figure 4 shows the microscopic effect of 120 min of
warm ischemia, 24 h after reperfusion, as compared
to the right (non-ischemic) lung. LIRI results in
intra-alveolar and septal edema, inflammation, at-
electasis and intra-alveolar hemorrhage.
Surfactant
Surfactant is responsible for decreasing the surface
tension between air and the alveolo-capillary mem-
brane. It thereby prevents the alveoli of the lung
from collapsing at the end of expiration, facilitating
inflation of the lung with minimal effort (12). In
addition, lowering the surface tension is important
for fluid homeostasis in the lung. Furthermore,
surfactant protects the lung against microorganisms
and serves as a functional barrier in the alveolus, so
that the transfer of molecules across the alveolo-
capillary membrane is limited. Finally, surfactant is
presumed to have immune downregulating effects
(12,19).
Surfactant is composed of lipids (90%) [mainly
dipalmitoyl-phosphatidylcholine (DPPC)] and sur-
factant-associated proteins (SPs) (10%). The pro-
teins can be divided into two groups: the hydrophilic
(SP-A and -D) and hydrophobic (SP-B and -C)
proteins (12,19).
The surface tension-lowering capacity of surfac-
tant is predominantly due to DPPC. SP-B and -C
have been demonstrated to enhance lipid insertion
into the monolayer at the airliquid interface. In this
way they protect the surface film from being
contaminated by non-surfactant proteins, which
degrade surfactant (12,19).
As a result of their ability to recognize a broad
spectrum of pathogens, SP-A and -D are believed to
be molecules of the innate immune system. Several
studies have shown that SP-A and -D interact with a
number of viruses, bacteria, fungi and allergens. SP-
A has also been suggested to play an important role
in phospholipid secretion and recycling, the forma-
tion of tubular myelin and the blocking of surfactant
inhibition by serum proteins (12,19).
Fig. 3. Dorsal macroscopic view of rat lungs which underwent
120 min of left lung warm ischemia and 180 min of ventilation
after reperfusion. The right lung did not suffer LIRI.
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Surfactant can be divided by ultra centrifugation
into two subfractions, which differ in terms of their
morphological appearance and density. The heavy
subtype or large aggregate (LA) subform of surfac-
tant is highly surface-active, contains a high amount
of SPs and is comprised of tubular myelin, lamellar
bodies and large vesicles. The light subtype or small
aggregate (SA) subform has a poor surface tension-
lowering capacity and consists of small vesicles.
When a lung is damaged, conversion of LAs to
SAs occurs, resulting in an increased SA:LA ratio
(7,10,12,19).
Production and secretion of surfactant is done
by alveolar type II (ATII) cells. ATII cells and
alveolar macrophages are important for the recycling
of surfactant lipids, which is essential for maintain-
ing homeostasis of the endogenous surfactant pool
(1921).
Surfactant damage
Figure 5 summarizes the pathways by which LIRI
exerts a damaging effect on surfactant.
Surfactant-associated proteins
As mentioned before, SPs play an important role in
maintaining the quality of the surfactant lining of
the alveolar epithelium. SPs are damaged due to
the formation of proteases and ROS, resulting in
impairment of surfactant recycling (SP-A), the
ability to block surfactant inhibition by serum
proteins (SP-A) and lipid insertion (SP-AC).
Decreased levels or inactivation of SPs can result
in a diminished quantity of phospholipids, but also
in a changed composition of surfactant, thereby
impairing surfactant-lowering properties (22).
A decrease in SP-AC was measurable after
prolonged ischemic storage without reperfusion
and it decreased further after the start of reperfusion
(22). Moreover, in lung transplant recipients, the
level of SP-A was found to be decreased /1 year
after transplantation (23). It was also shown (24)
that the level of SP-A decreased with increasing
severity of LIRI, suggesting that preservation of SP-
A is essential for improvement after LIRI.
Some studies (7,8) have reported surfactant dys-
function without an alteration in the overall amount
of phospholipid, but with changes in surfactant
composition, which could be the result of impaired
SPs. Both decreases in DPPC and phosphatidyl-
glycerol and an increase in sphingomyelin have been
described (7,8,22,25).
Plasma proteins
The presence of plasma proteins in the alveoli after
LIRI has been described in many studies
(7,8,22,24,2635). Both warm and cold ischemic
intervals have resulted in increased levels of plasma
protein 124 h after reperfusion (7,8,24,2629).
Owing to ROS, proteolytic enzymes and phospholi-
pases, endogenous surfactant and the endothelial
and epithelial membranes are damaged (2,15). This
results in leakage of serum proteins into the alveolus
and of surfactant components into the bloodstream.
As surfactant is rate-limiting for the transfer of
proteins across the alveolo-capillary membrane and
is either inactivated or lost due to the increased
endothelial permeability after LIRI, a further influx
Fig. 4. Microscopic views of (A) a left and (B) a right rat lung which underwent 120 min of left lung warm ischemia. Histological assessment
was made 24 h after reperfusion.
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of proteins is facilitated. Because proteins, once
accumulated in the alveolus, then dose-dependently
inhibit surfactant, this results in a self-triggering
mechanism of surfactant inactivation (36). Under
normal conditions, SP-A is partly able to counteract
the inactivating effects of serum proteins (37).
However, after LIRI, a decrease in SP-A was found
in human lung transplant recipients and in animal
models of LIRI (23,24).
Surfactant therapy
Because damaged surfactant contributes to symp-
toms seen with PAGF, surfactant replacement ther-
apy has been investigated using experimental ARDS
and LIRI models (9,22,24,2631,38,39). The effect
of surfactant therapy has also been investigated in
some case studies.
Clinical (case) studies
In 1995, Struber et al. (40) reported on a 26-year-
old female who underwent right lung transplanta-
tion and developed severe LIRI 5 h after trans-
plantation. She was subsequently treated with an
intrapulmonary nebulized synthetic surfactant.
Shortly afterwards, lung compliance, PaO2 and
tidal volume increased. Moreover, 24 h after
therapy, the edematous infiltrate of the trans-
planted lung observed on chest X-ray film was
resolved. Another study (41) in 6 lung transplant
patients also suggested improvement in LIRI due
to surfactant replacement. However, in 1 of the 6
recipients, surfactant therapy failed, which could
be attributed to the application approach or to the
type of surfactant used.
Experimental studies
Although surfactant damage can be reduced by
changing the preservation solution from Euro-Col-
lins to low-potassium dextran solution, and by
flushing the graft in a retrograde instead of an
antegrade fashion, there is still a rationale for using
surfactant replacement therapy in the case of severe
LIRI (3135,42). It was demonstrated (26,28) that
surfactant administration improved lung compliance
and PaO2 and prevented an increase in the SA:LA
ratio.
Most studies in which the effect of surfactant
replacement therapy has been investigated have only
addressed the first hours after reperfusion. Longer-
term studies of LIRI and surfactant treatment are
scarce. In this regard, Erasmus et al. (38) demon-
strated that surfactant treatment just before reperfu-
sion enhanced recovery from LIRI 1 week
postoperatively. We confirmed (10) that LIRI re-
sulted in an increased SA:LA ratio and in impaired
PaO2 and lung compliance throughout the first week
after reperfusion. However, even months after re-
Fig. 5. ROS directly damage (A) the alveolo-capillary membrane, thereby facilitating the influx of serum proteins into the alveolus, (B) SP,
(C) ATII cells and (D) the LA surfactant subform. Phospholipases cause degradation of (E) surfactant phospholipids inside the alveolus,
(F) the membranes of ATII cells and (G) capillary endothelium, resulting in the influx of serum proteins. Proteinases break down (H) SP-A
and (J) SP-B and -C. (K) Edema results in dilution of the surfactant phospholipids inside the alveolus, which results in further formation of
edema. A decrease in SP-A leads to (1) less inhibition of serum proteins and (2) decreased phospholipid secretion, recycling and formation
of tubular myelin. (3) Degradation of SP-B and -C causes less phospholipids to be inserted into the phospholipid monolayer lining the
alveolar epithelium. (4) Once serum proteins have infiltrated the alveolus, they compete for a place at the airliquid interface, thereby dose-
dependently inhibiting surfactant function. Furthermore, once the phospholipid monolayer is damaged, the molecule transfer-limiting
function of surfactant is also impaired, resulting in further influx of serum proteins, so that a vicious circle has developed. (5) ATII cells,
which are important in the production, recycling and secretion of surfactant phospholipids are damaged, so that less LA is secreted and a
smaller amount of SA is being recycled. Owing to these factors, a decrease in LA and an increase in SA has been noticed after LIRI.
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perfusion, diffuse alveolar damage and decreased
lung compliance were still visible (NP van der
Kaaij, unpublished observations, 2005). Surfactant
pretreatment completely normalized these para-
meters from Day 3 to Day 90 after reperfusion (10).
Pre- or post-treatment
Some studies (28,4345) have suggested that treat-
ment with exogenous surfactant before the onset of
ischemia is more beneficial compared to treatment at
or after reperfusion. This can be explained as the
result of an enlarged surfactant pool before the lung
sustains LIRI, which prevents deterioration of the
entire endogenous surfactant pool as a result of
LIRI. This can be illustrated by the fact that the
normal endogenous surfactant pool is :/1015 mg
lipid/kg, and that the amount of surfactant used for
treatment is in the range 50400 mg lipid/kg (9,44).
It was shown that the size of the surfactant pool is
inversely proportional to the duration of ischemia
because of the remaining activity of phospholipases
during ischemia, so that enlargement of the pool
before ischemia reduces the risk of total inactivation
of the surfactant pool.
Pretreatment also has the advantage of preserving
the endogenous SPs, although some (natural) sur-
factants may contain SP-B and -C. Also, surfactant
given to the donor results in a more homogeneous
distribution as compared to treatment after reperfu-
sion, when alveolar damage has already occurred
(Fig. 6) (9). In the latter case, intratracheally
instilled surfactant will predominantly accumulate
in open areas of the lung instead of atelectatic areas,
where it is most needed.
Although surfactant pretreatment seems more
beneficial than treatment after LIRI, the clinical
use of pretreatment in human lung transplantation is
inhibited by the cost of the material. Therefore, if
surfactant pretreatment is to be considered in the
clinical setting, the cost of surfactant must be
weighed against the possible improved outcome
and shorter hospitalization period.
The pathways of surfactant therapy for LIRI
The rationale behind surfactant replacement therapy
is to ameliorate the damage caused by ROS, to
preserve the levels of DPPC and SPs and to decrease
the inhibitory effects of serum proteins.
Anti-inflammatory and antioxidant function
Surfactant has been shown to inhibit cytokine release
from activated monocytes and macrophages (46,47);
the modulation of lymphocytes has also been sug-
gested (10). Furthermore, surfactant is known to
have antioxidant capacities, resulting in reduced
ROS injury (48). Surfactant treatment can thus
ameliorate the effects of inflammatory cells, so that
endothelial and ATII cell injury is decreased, nor-
malizing capillary permeability and surfactant recy-
cling. It was shown (23) that the decreased function
of ATII cells after LIRI is prevented by surfactant
therapy.
Restoration or preservation of surfactant composition
Surfactant therapy mainly consists of administration
of the LA subform (DPPC), which is the active
surface tension-lowering form of surfactant, so that
the level of LA surfactant in the alveolus is restored,
which has a major impact on lung function. Surfac-
tant pretreatment preserves the level of LA before
the lung sustains ischemia and reperfusion, thereby
decreasing lung injury instead of treating it (10).
Fig. 6. The hypothesis that pretreatment of the lung is more
beneficial than treatment after development of LIRI. (1) Normal
alveoli (A) of the lung, in which the normal endogenous surfactant
system (yellow ) keeps the alveoli open at the end of expiration. (2)
Lung alveoli after the development of LIRI: the endogenous
surfactant system is inactivated, resulting in collapse of the alveoli
of the lung (A*). (3) Surfactant pretreatment results in an
homogeneous distribution of the exogenous surfactant (blue ), so
that all alveoli of the lung are optimally protected against forth-
coming injury. (4) Surfactant treatment after LIRI: exogenous
surfactant will predominantly accumulate in the open areas of the
lung, whereas it will not arrive in those areas of the lung where it is
most needed (A/), resulting in an inhomogeneous distribution of
the exogenous surfactant.
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Furthermore, restoring or preserving the levels of
SPs contributes to normal phospholipid recycling
and secretion (22). It was demonstrated (24) that
SP-A-enriched surfactant was able to improve lung
function after prolonged ischemia, whereas this was
not possible to the same extent with SP-A-deficient
surfactant. Also, a decrease in the LA subform was
found, indicating an increased recycling capacity of
the SP-A-enriched surfactant compared with SP-A-
deficient surfactant (24).
Decreasing the inhibitory effects of serum proteins
When the quantity of surfactant is low, its composi-
tion has changed or capillary permeability has
developed, serum proteins leak into the alveolus,
where they further interfere with surfactant (49).
Surfactant post-treatment may interrupt this vicious
circle by restoring the quantity and composition of
surfactant phospholipids (26,36,50,51).
Pretreatment with surfactant decreases capillary
permeability and preserves the composition and
quantity of surfactant phospholipid and the level of
SPs. Preservation of SP-A is important, due to its
inhibiting effect on serum proteins. Cockshutt et al.
(37) showed reversed inhibition of serum proteins
when SP-A was administered.
Conclusions
In an experimental setting, surfactant therapy for
severe LIRI has proven to be effective. However, in
human lung transplantation it has not yet become
standard treatment for PAGF. Further clinical stu-
dies should investigate whether surfactant (pre)treat-
ment is a realistic option in the field of human lung
transplantation.
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